Clinical and Diagnostic Laboratory Immunology, January 1998, p. 121-124, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Monoclonal Antibody Specific to Surface Antigen
on Candida krusei
Raymond
Robert,1,*
Odile
Faure,2
Arnaud
Carloti,3
Bernadette
Lebeau,2
Christian
Bernard,4
Agnès
Marot-Leblond,1
Renée
Grillot,2 and
Jean-Marcel
Senet1
Département de
Mycologie-Immunologie-Parasitologie, Faculté de Pharmacie 49100 Angers,1
Département de
Parasitologie-Mycologie Médicale et Moléculaire,
Faculté de Médecine de Grenoble, Université Joseph
Fournier, 38706 La Tronche Cedex,2
Laboratoire de Mycologie Fondamentale et Appliquée aux
Biotechnologies Industrielles, Faculté de Pharmacie,
Université Claude Bernard-Lyon 1, 69373 Lyon Cedex
08,3 and
SR2B, PAT Carrière
Beurrière, 49240 Avrillé,4 France
Received 9 June 1997/Returned for modification 29 August
1997/Accepted 27 October 1997
 |
ABSTRACT |
A monoclonal antibody (MAb; MAb 6B3) which reacts specifically with
a cell wall antigen found in all strains or isolates of Candida
krusei was developed. MAb 6B3 was extensively tested by immunofluorescence assay for cross-reaction with many
Candida, Cryptococcus,
Saccharomyces, Trichosporon, and
Rhodotorula species and was found to react only with the
species C. krusei. The specific epitope is expressed on the
surface of fungal cells and appears to reside on a protein moiety.
Taking into account the increasing importance of fluconazole-resistant
strains in nosocomial fungal infections, the very high degree of
specificity of this MAb for C. krusei could be useful for
the routine detection of C. krusei in culture or in tissue
samples.
 |
TEXT |
Among the members of the genus
Candida, Candida albicans, Candida
tropicalis, Candida glabrata, and Candida
parapsilosis formerly represented more than 80% of the usual
clinical Candida isolates, while Candida krusei
was only sporadically isolated (11) and was regarded as a
commensal organism (13, 24). During the past decade,
C. krusei has been recognized as a true pathogen, particularly in immunocompromised patients. The resistance of this
organism to fluconazole and the systematic use of this drug may explain
the significant increase in the numbers of C. krusei infections, (9, 20, 31). In contrast to C. albicans, only a few articles concerning the potential virulence
of C. krusei have been published (10, 12, 14, 15, 21,
22, 25, 26). Likewise, relatively few studies have been conducted
to characterize antigens of C. krusei, and no monoclonal
antibody (MAb) specific to this yeast has yet been developed. The
present study concerns the description of a MAb (MAb 6B3) specific for the species C. krusei.
C. krusei ATCC 44507 (American Type Culture Collection) was
used throughout this work unless otherwise indicated. Clinical isolates
of C. krusei, Candida spp., and other fungi
including Rhodotorula, Saccharomyces, and
Cryptococcus were obtained from the Mycology Laboratory of
the Medical Schools in the French cities of Angers, Grenoble, and Lyon.
Each isolate was identified by using the ID 32C system
(bioMérieux, Marcy l'Étoile-France). Among the
isolates of C. krusei tested, 43 were typed by restriction endonuclease analysis and hybridization with the CkF1,2 DNA probe as
described previously (1, 2).
Cultures were maintained on a Sabouraud glucose agar (SGA) slant
(bioMérieux) at 22°C, and blastoconidia were prepared by growing the cells on this medium for 48 h at 37°C. In some
experiments, the influences of growth in different media and at
different temperatures (22 and 37°C) on the surface expression
of the antigen reacting with MAb 6B3 were investigated. Seven
isolates of C. krusei and one isolate each of C. albicans, C. tropicalis, or C. glabrata were
cultured for 48 h in the following five media: SGA, SGA with chloramphenicol, SGA with gentamicin, 5% sheep blood Columbia agar,
and chocolate agar (bioMérieux).
Cell antigens were extracted by the following four methods: (i)
109 blastoconidia were incubated at 37°C with shaking in
1.5 ml of 50 mM EDTA-0.35 M 2-mercaptoethanol (2ME; pH 9; Sigma
Chemical Co., St. Louis, Mo.) for 30 min; (ii) 109
blastoconidia were digested with 1 ml of lyticase (1,000 U/ml; Arthrobacter luteus; ICN Pharmaceuticals France, Orsay,
France) containing 1 mM phenylmethylsulfonyl fluoride (Sigma) for
1 h and 30 min at 37°C with shaking; (iii) 109 cells
were incubated at 37°C in 1.5 ml of 2% (wt/vol) sodium dodecyl
sulfate (SDS; Sigma) (5, 18) for 30 min; and (iv) extraction
by dithiothreitol (DTT) (Sigma) was performed as described by Smail and
Jones (27). Solubilized antigenic components were recovered
by centrifugation at 12,000 × g for 15 min, and they were then dialyzed against distilled water and lyophilized.
Enzyme-linked immunosorbent assays (ELISAs) were performed in
triplicate in a microtitration plate (Falcon; Becton Dickinson, Lincoln
Park, N.J.). Each well was coated with 100 µl of C. krusei extract at 10 or 100 µg of protein/ml in phosphate-buffered saline (PBS), and the plates were incubated for 2 h at 37°C or
overnight at 4°C. After washing with PBS, the plates were blocked by
adding 200 µl of PBS containing 1% bovine serum albumin (fraction V; Sigma). After washing with PBS with 0.05% Tween 20 (PBST), assays were
performed by successively incubating the wells with the MAb for 1 h at 37°C, with a 1/2,000 dilution of a commercially available goat
anti-mouse immunoglobulin G (IgG) peroxidase conjugate in PBST (Caltag
Laboratories, South San Francisco, Calif.) for another hour and then
the substrate solution containing ortho-phenylendiamine dihydrochloride (Sigma) and hydrogen peroxide in phosphate citrate buffer (0.15 M; pH 5.0) for 30 min. All working volumes were 100 µl.
The enzyme reaction was stopped by the addition of 50 µl of 1 N
H2SO4 and optical densities were read with a
Titertek Multiscan instrument at 492 nm (Flow Laboratories, Inc.,
McLean, Va.). The absorbance values given are the averages of three
absorbance values.
SDS-polyacrylamide gel electrophoresis (PAGE) was performed by the
method of Laemmli (16). Briefly, the extracts being analyzed were dissolved in buffer containing 62.5 mM Tris-HCl and 2% (wt/vol) SDS. After boiling for 2 min or incubation at 56°C for 30 or 60 min,
40 µl of each extract containing 20 or 60 µg of protein was placed
on a 5 to 15% gradient polyacrylamide slab gel. Electrophoresis was
performed in a gel electrophoresis apparatus (GE-2/4; Pharmacia, Uppsala, Sweden). Subsequently, the gels either were stained with Coomassie blue or were electrophoretically transferred to
polyvinylidene difluoride sheets (Immobilon; Millipore Corp., Bedford,
Mass.) as described previously (28). After the transfer, the
membranes were blocked in 10% nonfat dry milk in PBST, washed in PBS,
incubated with 1:20 or 1:100 dilutions of the MAb, washed, and
incubated with peroxidase-labelled, affinity-purified goat anti-mouse
IgG (Caltag Laboratories). After the washings the sheets were placed in
substrate solution (3,3'-diaminobenzidine [Sigma] and hydrogen peroxide) for 30 min.
Indirect immunofluorescence assays (IFAs) were carried out as described
previously (19). A suspension of 106
blastoconidia/ml in PBS containing NaN3 (1
) was
prepared. Ten microliters of this suspension was placed in the wells on
microscope slides (Polylabo, Strasbourg, France), and the suspension
was allowed to dry at 30°C for 1 h. Twenty microliters of
hybridoma culture supernatant undiluted or diluted in PBS was dropped
over the cells. The slides were placed in a moist chamber at 37°C for 1 h and were then washed twice with PBS. Twenty microliters of fluorescein-conjugated goat anti-mouse immunoglobulin (Caltag Laboratories) was added to the slides at a dilution of 1:100 in PBS,
and the slides were then reincubated at 37°C for 30 min and then
washed twice with PBS. The preparations were in PBS containing 90%
glycerol when they were mounted onto the slides. The preparations were
examined with a Nikon microscope equipped with a reflected-light source
of fluorescence. The same procedure was used for immunofluorescence studies of yeast cells grown under various conditions and for blastoconidia that were treated with different reagents.
The antigens were characterized by heat, enzymatic, and chemical
agent treatments. The heat stabilities of the C. krusei
antigens recognized by the MAb were tested by heating 107
blastoconidia of C. krusei in 1 ml of PBS at 56°C for 30 or 60 min and at 100°C for 2 or 5 min. The effects of lyticase (2,000 U/ml; Sigma) and four proteases, pronase E (2.5 mg/ml; Merck, Darmstadt, Germany), proteinase K (16 µg/ml; Merck), trypsin (2.5 mg/ml; Sigma), and
-chymotrypsin (25 µg/ml; Merck), were tested by
incubating 107 blastoconidia for 30 min at 37°C with
shaking in 1 ml of enzymatic reagent in PBS. Control cells were
incubated with PBS alone. Periodate oxidation was performed for 1 h at room temperature in the dark with 107 blastoconidia
and 1 ml of 20 mM of sodium periodate in 20 mM aceto-acetate buffer (pH
5). After washing in this buffer, the blastoconidia were incubated for
30 min with 1 ml of 1% (wt/vol) glycine to block the aldehyde groups
generated by the periodate treatment and to prevent nonspecific
reactions of the antibodies. The cells were then washed in PBS. Control
cells were incubated with acetate buffer alone. Treatment with
EDTA-2ME, DTT, or SDS was carried out as described above. After
incubation with enzymes or chemical agents, the blastoconidia were
washed in PBS and were fixed to the wells of a microscope slide. The
antigenic activity of the treated blastoconidia was measured by IFA as
described above. All experiments were performed in triplicate.
Preparation of the MAb was carried out by immunization of BALB/c
mice (Iffa Credo, l'Arbresle, France) with three subcutaneous injections, at 2-week intervals, of 106 formalin-killed
blastoconidia emulsified in 100 µl of Freund's complete adjuvant
(Sigma) for the first injection and in Freund's incomplete adjuvant
(Sigma) for the following two booster injections. A final booster
injection of 105 formalin-killed blastoconidia in 100 µl
of 0.15 M NaCl was given intravenously 3 days before the mouse was
killed. Hybridoma cells were produced by the method described by
Dippold et al. (3). Splenocytes were fused with mouse
plasmocytoma X63/Ag.63 in the presence of 0.4% polyethylene glycol
1500 (Merck). The fusion products were diluted in 200 ml of selective
medium containing 100 µg of hypoxanthine, 15 µM thymidine, and 0.4 µM aminopterin (HAT medium; Sigma), and the mixture was plated out at
100 µl per well in 20 96-well trays. Ten days after fusion, aliquots of medium from wells with growing hybridomas were screened by IFA for
the production of antibodies directed to blastoconidia of C. krusei. Positive hybrids were immediately subcloned twice by
limiting dilution in 96-well plates and were stored in liquid nitrogen.
MAbs were obtained from confluent hybridoma cultures in a nonselective
medium.
Two fusions were carried out, and 593 hybridoma cell lines were
produced. Supernatants from 10 of these cell lines produced antibodies
that recognized C. krusei by IFA. Among them, only one of
the cell lines (6B3), preliminarily tested by IFA against blastoconidia
from other Candida species, indicated that it was specific
for C. krusei. This hybridoma secreted an IgG and was selected for further studies. To investigate the strain and species specificities of MAb 6B3, 73 isolates or strains of C. krusei, 138 isolates of other Candida species, and 27 isolates of other fungal genera were cultured on SGA for 48 h at
37°C and were examined by IFA for surface antigen expression. The
antigen recognized by MAb 6B3 was not detectable in genera other than
Candida (Table 1). In the
genus Candida, no binding to the other species of yeast
tested other than C. krusei was noticed under the conditions supporting cell development. All isolates and reference strains of
C. krusei were positive by IFA with MAb 6B3. Both
blastoconidia and pseudohyphae (when present) reacted with the MAb. The
results of control experiments performed without MAb 6B3 were found to be negative. According to these results, MAb 6B3 recognizes a specific
C. krusei epitope that is expressed on the surfaces of the
blastoconidia of C. krusei.
IFA values were not affected by heating the blastoconidia of C. krusei for 30 or 60 min at 56°C. However, no immunofluorescent reactivity was obtained after heating at 100°C. Pronase E and trypsin
treatment of C. krusei reduced strongly the level of
fixation of MAb 6B3. Preparations treated with other enzymes such as
proteinase K,
-chymotrypsin, or lyticase retained the
same activities as those treated with buffer. Exposure of C. krusei blastoconidia to sodium periodate, EDTA-2ME, DTT, or SDS
did not affect or weakly reduce the level of fixation of MAb 6B3 (Table
2).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Quantitative IFA titers of MAb 6B3 in culture supernatant
tested with treated C. krusei ATCC 44507 blastoconidia
|
|
Soluble extracts made with DTT, EDTA-2ME, SDS, or lyticase and tested
with MAb 6B3 by ELISA showed no positive signal. These extracts were
separated by SDS-PAGE and detected immunologically by using MAb 6B3 to
identify the apparent molecular mass of the antigenic component. None
of these extracts gave a positive reaction, whatever the temperature
(100, 56, or 37°C) or the time (2, 30, or 60 min) of sample treatment
before electrophoresis. Although the antigen was expressed on the
surface of C. krusei, it was not identified in the soluble
extracts tested by ELISA or Western blotting. These results suggest two
hypotheses: (i) MAb 6B3 recognizes a conformational or a native protein
epitope which is present on intact cells and which could be denatured
following chemical or enzymatic extraction or (ii) the antigen
recognized by MAb 6B3 may not be released in the extracts made with
EDTA-2ME, lyticase, DTT, or SDS. The hypothesis that antigen is
resistant to solubilization is strengthened by the results obtained by
IFA: MAb 6B3 still stains the blastoconidial surface after treatments
with the various chemicals or lyticase.
The variability of antigen expression was examined by observing the
surface reactivities of cells grown under various conditions. Incubation with MAb 6B3 revealed that antigen expression was detectable on the blastoconidia of C. krusei whatever medium or
temperature (22 or 37°C) was used. However, the reactivity observed
by IFA was low when the blastoconidia were obtained on blood agar
(Table 3).
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Quantitative IFA titers of MAb 6B3 against isolates of
C. krusei and other Candida spp cultured in SGA,
SGA with chloramphenicol, SGA with gentamicin, 5% sheep blood Columbia
agar, or chocolate agar
|
|
Tsuchiya et al. (29, 30) used polyclonal antibodies (PAbs)
to study the antigenic patterns of the more medically important yeasts
by cross-absorption experiments. For C. krusei, by using PAb, Fukazawa et al. (7, 8) and Tsuchiya et al.
(30) determined three main antigenic factors: factors 1, 5, and 11. Factor 11 was identified as C. krusei specific. The
antigen recognized by MAb 6B3 is different from factor 11, which
presents a mannan moiety. Several lines of evidence indicate that the
epitope recognized by MAb 6B3 presents a protein moiety. First, it was
susceptible to treatment with heat at 100°C. Second, treatment with
some proteolytic enzymes (pronase, trypsin) resulted in a strong
reduction of fluorescent staining. Finally, treatment of C. krusei blastoconidia by sodium periodate did not affect
recognition by the MAb.
In conclusion, we provide here the first report of the development of a
MAb which identifies a C. krusei-specific antigen. Its use
in the latex test described by Freydiere et al. (6) is
useful for the rapid and convenient identification of C. krusei colonies. A similar test, Bichrolatex Albicans (Fumouze
Diagnostics, Asnière, France), which uses a MAb (MAb LIB 3H8)
specific for C. albicans, was developed for the rapid
identification of C. albicans colonies (4, 17,
23). In addition, MAb 6B3 could also be used for the
identification of C. krusei in tissue samples or in normally
sterile fluids.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Mycologie, Faculté de Pharmacie, 16 boulevard Daviers 49100, Angers, France. Phone: 332-41-22-66-60. Fax: 332-41-48-67-33. E-mail: raymond.robert{at}univ-angers.fr.
 |
REFERENCES |
| 1.
|
Carlotti, A.,
A. Couble,
J. Domingo,
K. Miroy, and J. Villard.
1996.
Species-specific identification of Candida krusei by hybridization with the CkF1,2 DNA probe.
J. Clin. Microbiol.
34:1726-1731[Abstract].
|
| 2.
|
Carlotti, A.,
R. Grillot,
A. Couble, and J. Villard.
1994.
Typing of Candida krusei clinical isolates by restriction endonuclease analysis and hybridization with CkF1,2 DNA probe.
J. Clin. Microbiol.
32:1691-1699[Abstract/Free Full Text].
|
| 3.
|
Dippold, W. G.,
K. O. Lloyd,
L. T. C. Li,
H. Ikeda,
H. F. Oettgen, and L. J. Old.
1980.
Cell surface antigens of human malignant melanoma; definition of six antigenic systems with mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. USA
77:6114-6118[Abstract/Free Full Text].
|
| 4.
|
Dromer, F., and B. Dupont.
1996.
The increasing problem of fungal infections in the immunocompromised host.
J. Mycol. Med.
6:1-6.
|
| 5.
|
Elorza, M.,
A. Marcilla, and R. Sentandreu.
1988.
Wall mannoproteins of the yeast and mycelial cells of Candida albicans: nature of the glycosidic bonds and polydispersity of their mannan moieties.
J. Gen. Microbiol.
134:2393-2403[Medline].
|
| 6.
|
Freydiere, A. M.,
L. Buchaille,
R. Guinet, and Y. Gille.
1997.
Evaluation of latex reagents for rapid identification of Candida albicans and C. krusei colonies.
J. Clin. Microbiol.
35:877-880[Abstract].
|
| 7.
|
Fukazawa, Y.,
T. Shinoda,
A. Nishikawa,
K. Kagaya, and Y. Yonezawa.
1976.
Serological and immunological studies of the serotypes of Candida albicans, p. 213.
In
K. Iwata (ed.), Yeasts and yeast-like microorganisms in medical science. University of Tokyo Press, Tokyo, Japan.
|
| 8.
|
Fukazawa, Y.,
T. Shinoda, and T. Tsuchiya.
1968.
Response and specificity of antibodies for Candida albicans.
J. Bacteriol.
95:754[Abstract/Free Full Text].
|
| 9.
|
Horn, R.,
B. Wang,
T. Kiehn, and D. Armstrong.
1985.
Fungemia in a cancer hospital: changing frequency, earlier onset and results of therapy.
Rev. Infect. Dis.
7:646-655[Medline].
|
| 10.
|
Howlett, J. A.
1975.
The infection of rat tongue mucosa in vitro with five species of Candida.
J. Med. Microbiol.
9:309-316[Abstract].
|
| 11.
|
Hurley, R.,
J. De Louvois, and A. Mulhall.
1987.
Yeasts as human and animal pathogens, p. 207-281.
In
A. H. Rose, and J. S. Harrison (ed.), The yeasts, 2nd ed, vol. 1. Academic Press, London, United Kingdom.
|
| 12.
|
Hurley, R., and V. C. Stanley.
1969.
Cytopathic effects of pathogenic and non-pathogenic species of Candida on cultured mouse epithelial cells: relation of the growth rate and morphology of the fungi.
J. Med. Microbiol.
2:63-74[Medline].
|
| 13.
|
Hurley, R., and H. I. Winner.
1966.
Pathogenicity in the genus Candida.
Dermatol. Int.
5:151-153.
|
| 14.
|
King, R.,
R. Lee, and A. Morris.
1980.
Adherence of Candida albicans and other Candida spp. to mucosal epithelial cells.
Infect. Immun.
27:667-674[Abstract/Free Full Text].
|
| 15.
|
Klotz, S. A.,
D. J. Drutz, and J. E. Zajic.
1985.
Factors governing adherence of Candida species to plastic surfaces.
Infect. Immun.
50:97-101[Abstract/Free Full Text].
|
| 16.
|
Laemmli, U. K.
1970.
Cleavage of structural proteins during the assembly of the head of bacteriophage T4.
Nature
227:680-685[Medline].
|
| 17.
|
Laurent, F.,
P. Cahen, and P. Honderlick.
1996.
Utilization of the Bichrolatex albicans® Fumouze for rapid identification of Candida albicans in blood culture bottles.
J. Mycol. Med.
6:19-21.
|
| 18.
|
Marcilla, A.,
S. Mormeneo,
M. V. Elorza,
J. J. Manclus, and R. Sentandreu.
1993.
Wall formation by Candida albicans yeast cells synthesis, secretion and incorporation of two types of mannoproteins.
J. Gen. Microbiol.
139:2985-2993[Medline].
|
| 19.
|
Marot-Leblond, A.,
R. Robert,
J. M. Senet, and T. Palmer.
1995.
Purification of a Candida albicans germ tube specific antigen.
FEMS Immunol. Med. Microbiol.
12:127-136[Medline].
|
| 20.
|
Merz, W. G.,
J. E. Karp,
D. Schron, and R. Saral.
1986.
Increased incidence of fungemia caused by Candida krusei.
J. Clin. Microbiol.
24:581-584[Abstract/Free Full Text].
|
| 21.
|
Miyake, Y.,
Y. Fuyita,
S. Minagi, and H. Suginaka.
1986.
Surface hydrophobicity and adherence of Candida albicans to acrylic surfaces.
Microbios
46:7-14[Medline].
|
| 22.
|
Ray, T. L.,
K. B. Digre, and C. D. Payne.
1984.
Adherence of Candida spp to human epidermal corneocytes and buccal mucosal cells: correlation with cutaneous pathogenicity.
J. Invest. Dermatol.
83:37-41[Medline].
|
| 23.
|
Robert, R.,
R. Sentandreu,
C. Bernard, and J.-M. Senet.
1994.
Evaluation du réactif Bichrolatex albicans pour l'identification rapide de colonies de Candida albicans.
J. Mycol. Med.
4:226-229.
|
| 24.
|
Samaranayake, Y. H., and L. P. Samaranayake.
1994.
Candida krusei: biology, epidemiology, pathogenicity and clinical manifestations of an emerging pathogen.
J. Med. Microbiol.
41:295-310[Abstract].
|
| 25.
|
Samaranayake, Y. H.,
P. C. Wu,
L. P. Samaranayake,
M. So, and K. Y. Yuen.
1994.
Adhesion and colonisation of Candida krusei on host surfaces.
J. Med. Microbiol.
41:250-258[Abstract].
|
| 26.
|
Segal, E.,
O. Lehrman, and D. Dayan.
1988.
Adherence in vitro of various Candida species to acrylic surfaces.
Oral Surg. Oral Med. Oral Pathol.
66:670-673[Medline].
|
| 27.
|
Smail, E. H., and J. M. Jones.
1984.
Demonstration and solubilization of antigens expressed primarily on the surfaces of Candida albicans germ tubes.
Infect. Immun.
45:74-81[Abstract/Free Full Text].
|
| 28.
|
Towbin, H.,
T. Staehelin, and J. Gordon.
1979.
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications.
Proc. Natl. Acad. Sci. USA
76:4350-4354[Abstract/Free Full Text].
|
| 29.
|
Tsuchiya, T.,
Y. Fukazawa, and S. Kawakita.
1965.
Significance of serological studies on yeasts.
Mycopathol. Mycol. Appl.
26:1[Medline].
|
| 30.
|
Tsuchiya, T.,
M. Taguchi,
Y. Fukasawa, and T. Shinoda.
1984.
Serological characterization of yeasts as an aid in identification and classification.
Methods Microbiol.
16:75.
|
| 31.
|
Wingard, J. R.,
W. G. Merz,
M. G. Rinaldi,
T. R. Johnson,
J. E. Karp, and R. Saral.
1991.
Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole.
N. Engl. J. Med.
325:1274-1277[Abstract].
|
Clinical and Diagnostic Laboratory Immunology, January 1998, p. 121-124, Vol. 5, No. 1
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.